Compare First Solar, Inc. (FSLR) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Heron Therapeutics Inc — how do they compare? First Solar, Inc. trades at $177.82 (market cap $19.22B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: First Solar, Inc. is far larger — about 282.6× Heron Therapeutics Inc's market cap, and First Solar, Inc. is more actively traded (2,067,793 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Heron Therapeutics Inc for 35 Days on average.
| FSLR | HRTX | |
|---|---|---|
Market Cap | $19.22B | $68.01M |
Volume | 2,067,793 | 1,891,941 |
Sector | Energy | Health |
52-Week High | $318.30 | $1.49 |
52-Week Low | $172.11 | $0.27 |
Typical Hold Time | 76 Days | 35 Days |
Enterprise Value | $17.69B | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $178.85, down 0.71% on the day, with a bearish technical signal and key support at $175. Fundamentally, the company shows strong profitability with a 32.47% net income margin and robust revenue growth, though it recently missed Q4 2025 EPS estimates. Recent news includes a patent lawsuit filing and elevated put option activity, reflecting mixed sentiment amid sector-wide pressures from high borrowing costs.
The outlook balances solid fundamentals against near-term headwinds. Analyst consensus is bullish with a $267.59 price target, but risks include solar industry volatility, interest rate sensitivity, and competitive challenges. Earnings growth and execution on guidance are critical for stock performance.
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
